Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Christine M HeskeYueh-Yun ChiRajkumar VenkatramaniMinjie LiMichael A ArnoldRoshni DasguptaSusan M HinikerDouglas S HawkinsLeo MascarenhasPublished in: Cancer (2020)
Patients with localized, FOXO1 fusion-positive RMS can be further risk stratified based on clinical features at diagnosis, and older patients with large primary tumors have the poorest prognosis.